Argos Therapeutics (ARGS) Misses Q2 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Argos Therapeutics Reports Second Quarter 2016 Financial Results and Recent Operational Highlights
August 10, 2016 4:06 PM EDT- Independent Data Monitoring Committee Recommended Continuation of Phase 3 ADAPT Trial of AGS-003 in Metastatic Renal Cell Carcinoma -
- Closed on $29.8 million Second Tranche of March 2016 Financing -
- Raised Gross Proceeds of $50.0 million in Follow-on Offering -Â
- Entered into Strategic Research Agreement with Adaptive Biotechnologies -
- Company Added to the Russell 2000® Index -
- Conference Call and Webcast Today, August 10th, at 4:30 p.m. ET -
DURHAM, N.C., Aug. 10, 2016... More
